LitCovid-sentences  

PMC:7455510 / 3698-10217 JSONTXT 10 Projects

Annnotations TAB TSV DIC JSON TextAE-old TextAE

Id Subject Object Predicate Lexical cue
T33 0-7 Sentence denotes Results
T34 8-129 Sentence denotes During the month of March, a total of 315 children were tested in our hospital for SARS-CoV-2 and 51 were positive (16%).
T35 130-185 Sentence denotes Twenty-eight of the positive cases (55%) were admitted.
T36 186-287 Sentence denotes A total of 8 positive cases (15%) were immunosuppressed patients, and 3 were followed as outpatients.
T37 288-587 Sentence denotes The underlying pathology was hemato-oncological in most cases (three patients had undergone a hematopoietic stem cell transplant), two patients had undergone a liver or a kidney transplant, and the last case was a girl on chronic hemodialysis with a vasculitis receiving immunosuppressive treatment.
T38 588-654 Sentence denotes The median age was 12.6 years (interquartile range: IQR 9.5–12.6).
T39 655-760 Sentence denotes All the patients had been on immunosuppressive treatment with a median duration of 24 months (IQR 12–93).
T40 761-898 Sentence denotes All had respiratory symptoms, 5 of them had fever, and the majority had slight radiological alterations (only two had focal infiltrates).
T41 899-964 Sentence denotes In only one case the chest X-ray worsened during hospitalization.
T42 965-1025 Sentence denotes One patient needed oxygen therapy and one case had diarrhea.
T43 1026-1062 Sentence denotes None of them had anosmia or ageusia.
T44 1063-1326 Sentence denotes One patient developed a hemophagocytic lymphohistiocytosis-like syndrome (sHLH), with persistent fever, cytopenias, low fibrinogen and elevated triglycerides, and elevated ferritin, and required specific treatment with dexamethasone, as per the HLH-2004 protocol.
T45 1327-1715 Sentence denotes Antiviral treatment was initiated according to our National guidelines, developed by the National Infectious Disease Society (SEIP), in coordination with the National Pediatric Intensive Care Society (SECIP) and the National Pediatric Association (AEP) available at https://www.aeped.es/noticias/documento-manejo-clinico-paciente-pediatrico-y-pacientes-riesgo-con-infeccion-por-sars-cov2.
T46 1716-1982 Sentence denotes Hydroxychloroquine was initiated upon diagnosis (positive PCR for SARS-CoV-2) when there were signs/ symptoms of moderate-severe disease (respiratory signs, pneumonia on chest X ray, blood parameters of severity such as lymphopenia or elevated CRP, D-dimer or Il-6).
T47 1983-2059 Sentence denotes Remdesivir was requested, under compassionate use, in the most severe cases.
T48 2060-2192 Sentence denotes Following theses guidelines, in 5/8 cases, some antiviral treatment was prescribed, with hydroxychloroquine being the most frequent.
T49 2193-2505 Sentence denotes Two patients received remdesivir (the two oncological patients who required admission: patient 1 who had oxygen requirement and patient 4 who had persistent symptoms with severe lymphopenia and elevated inflammatory parameters) and only one patient received tocilizumab due to persistent fever and elevated IL-6.
T50 2506-2577 Sentence denotes There were no significant toxicities following the treatments received.
T51 2578-2725 Sentence denotes Immunosuppressive therapy was decreased or withdrawn in 6 patients (the other two had been off immunosuppression for 1 and 2 months, respectively).
T52 2726-2777 Sentence denotes All but one case developed progressive lymphopenia.
T53 2778-2810 Sentence denotes D-dimer was moderately elevated.
T54 2811-2959 Sentence denotes With a median follow up of 106 days (IQR 103–113) from COVID-19 diagnosis, no child required admission to the pediatric intensive care unit or died.
T55 2960-3084 Sentence denotes At present, all the patients are being followed up as outpatients and have had no further complications related to COVID-19.
T56 3085-3201 Sentence denotes The clinical characteristics of the patients, as well as details on the treatment received, are outlined in Table 1.
T57 3202-3286 Sentence denotes Table 1 Clinical characteristics of immunocompromised children with COVID-19 disease
T58 3287-3309 Sentence denotes Case # 1 2 3 4 5 6 7 8
T59 3310-3351 Sentence denotes Age (years) 15 13 12.6 9 6.7 11 12.6 14.8
T60 3352-3374 Sentence denotes Gender F M M M M M F M
T61 3375-3395 Sentence denotes Primary disease HSCT
T62 3396-3423 Sentence denotes PID (CTLA4 deficiency) HSCT
T63 3424-3453 Sentence denotes Myelodysplastic syndrome HSCT
T64 3454-3502 Sentence denotes B-ALL T-ALL Melanoma Liver Tx C-ANCA vasculitis.
T65 3503-3525 Sentence denotes Hemodialysis Kidney Tx
T66 3526-3598 Sentence denotes Immunosuppressive treatment/targeted therapy None (stopped for 1 month).
T67 3599-3609 Sentence denotes CD4 cells:
T68 3610-3658 Sentence denotes 216/ μL Ruxolitinib None (stopped for 2 months).
T69 3659-3669 Sentence denotes CD4 cells:
T70 3670-3816 Sentence denotes 30/ μL Oral mercaptopurine and methotrexate Trametinib Prednisone, tacrolimus Prednisone, azathioprine Prednisone, tacrolimus, mycophenolate (MMF)
T71 3817-3851 Sentence denotes Fever Yes No Yes Yes No Yes Yes No
T72 3852-3886 Sentence denotes Cough No No No Yes Yes Yes Yes Yes
T73 3887-3924 Sentence denotes Sore throat No Yes No No No No Yes No
T74 3925-3957 Sentence denotes Dyspnea Yes No No No No No No No
T75 3958-3973 Sentence denotes Lymphocytes/mm3
T76 3974-4024 Sentence denotes (minimum value) 730 1210 520 340 2730 970 380 1620
T77 4025-4038 Sentence denotes D-dimer ng/mL
T78 4039-4082 Sentence denotes (maximum value) 301 - 418 1143 370 - 1168 -
T79 4083-4133 Sentence denotes IL-6 pg/mL (maximum value) 9.60 2.30 - 192 - - - -
T80 4134-4193 Sentence denotes C- Reactive Protein (mg/L) 26.2 1.9 18.9 24.6 0.6 0.9 9 106
T81 4194-4264 Sentence denotes Ferritin (mg/dl) Not done Not done 622 1534 Not done Not done 1270 553
T82 4265-4283 Sentence denotes Chest X-ray Normal
T83 4284-4293 Sentence denotes (Previous
T84 4294-4488 Sentence denotes lobectomy) Interstitial infiltrate Interstitial infiltrate Interstitial infiltrate Focal infiltrate Mild parahilar infiltrates Normal initially but focal infiltrate on evolution Focal infiltrate
T85 4489-4542 Sentence denotes Required hospitalization Yes No No Yes No Yes Yes Yes
T86 4543-4557 Sentence denotes Treatment HCQ*
T87 4558-4603 Sentence denotes Remdesivir** IS withdrawal HCQ* IS withdrawal
T88 4604-4608 Sentence denotes HCQ*
T89 4609-4621 Sentence denotes Remdesivir**
T90 4622-4633 Sentence denotes Tocilizumab
T91 4634-4757 Sentence denotes Dexamethasone*** Trametinib withdrawal Reduction in IS (50% tacrolimus reduction) Reduction in IS (azathioprine withdrawal)
T92 4758-4765 Sentence denotes LPV/Rtv
T93 4766-4848 Sentence denotes HCQ* Reduction in IS (MMF withdrawal, tacrolimus decrease and prednisone increase)
T94 4849-4853 Sentence denotes HCQ*
T95 4854-4895 Sentence denotes Duration of stay (days) 11 - - 28 - 3 4 2
T96 4896-5005 Sentence denotes Complications O2 requirement on nasal cannula (maximun 2 lpm) None None HLH-like syndrome None None None None
T97 5006-5102 Sentence denotes F female, M male, HSCT: hematopoietic stem cell transplant, PID primary immunodeficiency, B-ALL:
T98 5103-5323 Sentence denotes B cell acute lymphoblastic leukemia, T-ALL T cell acute lymphoblastic leukemia, Tx transplant, HCQ hydroxychloroquine, IS immunosuppressors, LPV/Rtv lopinavir/ritonavir, O2 oxygen; HLH hemophagocytic lymphohistiocytosis.
T99 5324-5341 Sentence denotes MMF mycophenolate
T100 5342-5503 Sentence denotes *HCQ was initiated in patients 1, 3, 4, and 8 once confirmation of positive SARS-CoV-2 with a nasal swab was obtained (< 24 h from consultation at our hospital).
T101 5504-5601 Sentence denotes Patients 1, 3, and 8 attended the Emergency Department in the first 24 h after onset of symptoms.
T102 5602-5768 Sentence denotes Patient 4 had fever of 4 days when the nasal swab was obtained, and patient 7 received 5 days of LPV/Rtv initially and due to persistent symptoms was switched to HCQ.
T103 5769-5973 Sentence denotes According to our guidelines, the oral dose was as follows: HCQ 6.5 mg/kg/day (dosing q12 h) in 6 year-olds, and HCQ 10 mg/kg/day (dosing q12 h) in children > 6 years (maximum daily dose 400 mg) for 5 days
T104 5974-6258 Sentence denotes **Remdesivir was given for a total of 7 days on patient 1 and 10 days on patient 4, at an intravenous dose of 5 mg/kg on day 1, followed by a maintenance dose of 2.5 mg/kg from days 2 to 9 (patients <40 kg) or 200 mg/iv on day 1 followed by 100 mg/iv on days 2-9 (for patients >40 kg)
T105 6259-6346 Sentence denotes ***Dexamethasone was given as per the HLH 2004 trial, although with a shorter duration:
T106 6347-6519 Sentence denotes 10 mg/m2/day for 7 days, followed by 5 mg/m2/day for another 7 days, followed by 2.5 mg/m2 for 7 days and 1.25 mg/m2 for 2 days and then a tapering dose with hydrocortisone